Morgan Stanley raised the firm’s price target on McKesson (MCK) to $810 from $770 and keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCK:
- McKesson CEO sells $13.7M in common stock
- Oncology Institute names Kristin England chief administrative officer
- Synergy CHC secures retail deals with McKesson Canada, others
- Cardinal Health price target raised to $181 from $166 at Morgan Stanley
- McKesson’s Operational Strength and Strategic Acquisition Drive Positive Outlook